Boston Scientific Corporation $BSX Shares Bought by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 72.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,000 shares of the medical equipment provider’s stock after buying an additional 16,000 shares during the period. Boston Scientific accounts for about 1.2% of Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings, making the stock its 22nd largest holding. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Boston Scientific were worth $2,384,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BSX. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Colonial Trust Co SC grew its position in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares during the last quarter. Finally, Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.6%

BSX opened at $44.20 on Friday. The business has a 50 day moving average price of $53.28 and a two-hundred day moving average price of $71.32. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a market cap of $65.70 billion, a PE ratio of 18.50, a P/E/G ratio of 0.85 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $43.89 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has authorized a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific’s growth prospects, pointing to upcoming catalysts like pulse field ablation (PFA) and Watchman, and TD Cowen reiterated a Buy rating with a lowered price target that still implies meaningful upside. TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)
• Positive Sentiment: Unusually heavy call option buying suggests traders are positioning for a rebound in BSX, which can reflect bullish near-term sentiment.
• Positive Sentiment: Short interest fell sharply in June, dropping 48.3% to about 29.8 million shares, which may indicate easing bearish conviction and could reduce downside pressure.
• Positive Sentiment: One commentary piece argued that Boston Scientific’s pullback may be creating a value opportunity, reinforcing the view that some investors see the stock as oversold. Boston Scientific’s Fall From Penthouse To Doghouse Creates A Value Opportunity
• Neutral Sentiment: A recent note said BSX has been a laggard this year, and although analysts see upside from current levels, the stock is still working to recover from a sharp decline.
• Negative Sentiment: Boston Scientific recently disclosed a nationwide recall of Orca valves after a device malfunction, adding regulatory and operational concerns that may weigh on sentiment. Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction
• Negative Sentiment: Investors also remain focused on questions around Watchman and the impact of the device recall, which have changed the investment story and may be contributing to recent stock weakness. How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock worth $554,012 in the last three months. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on BSX. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a research report on Thursday, April 23rd. Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Mizuho decreased their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Finally, Raymond James Financial restated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $83.36.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.